Skip to main content
Medivir logo

Medivir — Investor Relations & Filings

Ticker · MVIR ISIN · SE0020181014 LEI · 549300VWDGUX0WMJ1T79 ST Manufacturing
Open in API
Filings indexed 965 across all filing types
Latest filing 2013-12-10 Regulatory Filings
Country SE Sweden
Listing ST MVIR

About Medivir

https://www.medivir.com/

Medivir is a pharmaceutical company specializing in the discovery and clinical development of innovative drugs for cancer. The company focuses on oncology areas with high unmet medical needs, aiming to provide transformative treatments for patients with limited therapeutic options. Its research and development strategy is based on extensive expertise in drug design, particularly targeting enzymes such as proteases and polymerases, and includes the use of a proprietary prodrug platform. Medivir actively pursues collaborations with academic and industrial partners to advance its pipeline from research through to commercialization.

Recent filings

Filing Released Lang Actions
Simeprevir is now available for Hepatitis C patients in Japan, USA and Canada
Regulatory Filings Classification · 95% confidence The document is a short press release dated December 10, 2013, announcing the availability of the drug Simeprevir in Japan, USA, and Canada following recent approvals. It contains key business updates (product launch) but does not contain comprehensive financial statements (like 10-K or IR), detailed management discussion (MDA), or specific voting/dividend information. It is a general business announcement regarding a significant event (product launch/availability). Since it is not a specific financial report, earnings release (ER), or a report publication announcement (RPA) about a formal financial filing, the most appropriate general category for a significant, non-financial regulatory/business update that doesn't fit elsewhere is 'Regulatory Filings' (RNS), as it is a public disclosure required under securities law ('Medivir is required under the Securities Markets Act to make the information in this press release public').
2013-12-10 English
Simeprevir finns nu tillgängligt för hepatit C-patienter i Japan, USA och Kanada
Regulatory Filings Classification · 95% confidence The document is a press release dated December 10, 2013, announcing that the drug simeprevir is now available for prescription in Japan, the USA, and Canada for Hepatitis C treatment. It contains standard press release formatting, contact information for IR, and a concluding statement about the company's obligation to publicly disclose information according to securities market laws. This type of announcement, which is a general corporate update regarding product availability/approval and not a specific financial report (like 10-K, IR, ER) or a specific regulatory filing type (like DIRS, DIV), fits best under the general 'Regulatory Filings' category, which serves as a fallback for miscellaneous announcements that don't fit other specific codes. Given its nature as a general corporate news release, RNS (Regulatory Filings) is the most appropriate classification.
2013-12-10 Swedish
HELIX-2, a phase II all-oral combination study of Simeprevir, TMC647055 and Samatasvir (IDX719) for the treatment of hepatitis C has been initiated
Regulatory Filings Classification · 95% confidence The document is a press release dated December 2, 2013, announcing the initiation of a Phase II clinical trial (HELIX-2) for a hepatitis C treatment combination involving simeprevir, TMC647055, and samatasvir. It details the study design, the collaboration agreements, and provides background information on the drugs involved. This type of announcement, detailing operational or clinical progress outside of standard mandatory financial reporting (like 10-K or 10-Q), is typically classified as a general regulatory announcement or news release. Since it does not fit the specific definitions for Earnings Release (ER), Capital Update (CAP), or a specific legal/governance filing, the most appropriate general category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory announcements not covered elsewhere.
2013-12-02 English
Fas II kombinationsstudie med Simeprevir, TMC647055 och Samatasvir (IDX719) för behandling av hepatit C, HELIX-2, har inletts
Regulatory Filings Classification · 95% confidence The document is a press release dated December 2, 2013, announcing the initiation of a Phase II clinical study (HELIX-2) involving several antiviral drugs for Hepatitis C treatment. It details the study design, patient population, and provides background information on the drugs involved (Simeprevir, TMC647055, Samatasvir). This type of announcement, focusing on clinical trial progress and drug development updates, is characteristic of investor relations communication, but it is not a formal regulatory filing like a 10-K, a specific financial report (ER, IR), or a management change (MANG). Since it is an announcement regarding ongoing research and development activities, and it doesn't fit the specific categories like Capital/Financing (CAP), Legal (LTR), or Dividend (DIV), it falls best under the general category for corporate news that isn't strictly financial reporting or governance. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a general corporate announcement of this nature, although 'Investor Presentation' (IP) or 'Earnings Release' (ER) might be considered if it were a summary of results, which it is not. Since it is a press release announcing a clinical trial start, and it is not a formal regulatory form, RNS (Regulatory Filings/General Announcement) is the best fit as a catch-all for significant corporate news not covered elsewhere.
2013-12-02 Swedish
Simeprevir has been approved in the USA as a new treatment for hepatitis C
Regulatory Filings Classification · 95% confidence The document is a 'Press Release' dated November 23, 2013, announcing a significant corporate event: the FDA approval of the drug simeprevir. It details the implications of this approval, including a milestone payment (€10m) to Medivir, and provides background on the drug and the company. This type of announcement, which communicates a major business development (drug approval, milestone achieved, partnership update) outside of routine financial reporting (like 10-K or ER), typically falls under general regulatory announcements or news releases. Since it is not a formal financial report (10-K, IR, ER, MRQ), nor a specific filing like DIRS, DIV, or DEF 14A, the most appropriate classification is Regulatory Filings (RNS), which serves as the general category for miscellaneous regulatory announcements that don't fit elsewhere, especially when issued as a press release. It is not an Earnings Release (ER) as it focuses on regulatory/product news, not period financial results. It is not an Investor Presentation (IP) or Fund Factsheet (FS). It is a news announcement, making RNS the best fit.
2013-11-23 English
Simeprevir har godkänts i USA som behandling mot hepatit C
Regulatory Filings Classification · 95% confidence The document is a press release dated November 23, 2013, announcing that the drug Simeprevir has been approved by the US FDA for treating Hepatitis C. It details the approval, mentions milestone payments, and provides background information on the drug and the company (Medivir AB). This type of announcement, focusing on a specific corporate event (drug approval triggering a payment) that is not a standard periodic financial report (like 10-K or IR) or a general earnings release (ER), fits best under the general 'Regulatory Filings' (RNS) category, as it is a significant, time-sensitive regulatory/corporate update that doesn't match the more specific categories like DIV, CAP, or MANG. Given the context of a press release announcing a regulatory milestone, RNS is the most appropriate general regulatory announcement category.
2013-11-23 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.